Tenaya Therapeutics (TNYA) News Today $2.13 -0.06 (-2.74%) (As of 09/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by BrokeragesSeptember 10, 2024 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has earned a consensus rating of "Buy" from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target priceSeptember 10, 2024 | marketbeat.comTenaya Therapeutics to Participate in Upcoming Investment ConferencesSeptember 3, 2024 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Insider Whittemore Tingley Sells 7,428 SharesAugust 17, 2024 | insidertrades.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year targAugust 16, 2024 | marketbeat.comVanguard Group Inc. Increases Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Vanguard Group Inc. boosted its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 16.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,862,916 shares of the company's stock afteAugust 13, 2024 | marketbeat.comBuy Rating on Tenaya Therapeutics: Promising Clinical Trials and Solid Financial PositionAugust 10, 2024 | markets.businessinsider.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comPrice T Rowe Associates Inc. MD Sells 1,198,021 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Price T Rowe Associates Inc. MD reduced its holdings in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 26.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,346,522 shares of the cAugust 3, 2024 | marketbeat.com5 Penny Stocks With 250% Upside in 1 Year According to Wall StreetJuly 30, 2024 | 247wallst.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)July 26, 2024 | markets.businessinsider.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has earned a consensus rating of "Buy" from the eight research firms that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price target among broJuly 22, 2024 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday.July 8, 2024 | marketbeat.comTenaya Therapeutics Announces Research Leadership UpdatesJune 27, 2024 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price objective amoJune 27, 2024 | marketbeat.comTenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA SummitJune 18, 2024 | globenewswire.comChardan Capital Comments on Tenaya Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TNYA)Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Investment analysts at Chardan Capital dropped their FY2024 earnings estimates for shares of Tenaya Therapeutics in a report released on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now anticipates that the company will earn ($1.61May 31, 2024 | marketbeat.comWe're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 25, 2024 | finance.yahoo.comCanaccord Genuity Group Trims Tenaya Therapeutics (NASDAQ:TNYA) Target Price to $16.00Canaccord Genuity Group lowered their price objective on shares of Tenaya Therapeutics from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday.May 16, 2024 | marketbeat.comBuy Rating Affirmed for Tenaya Therapeutics on Strong Program Prospects and Financial StabilityMay 16, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday.May 15, 2024 | marketbeat.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024May 15, 2024 | investorplace.comTenaya Therapeutics Cutting Workforce by 22%May 14, 2024 | marketwatch.comTenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 14, 2024 | globenewswire.comTenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual MeetingMay 2, 2024 | globenewswire.comInstitutions own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares but private equity firms control 44% of the companyApril 14, 2024 | finance.yahoo.comShort Interest in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Increases By 21.2%Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 3,090,000 shares, a growth of 21.2% from the March 15th total of 2,550,000 shares. Based on an average trading volume of 609,900 shares, the days-to-cover ratio is currently 5.1 days. Currently, 5.0% of the company's shares are sold short.April 13, 2024 | marketbeat.comTenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy RatingApril 5, 2024 | markets.businessinsider.comOptimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical MilestonesMarch 29, 2024 | markets.businessinsider.com20 Countries with the Highest Heart Disease Deaths Per CapitaMarch 26, 2024 | finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)March 21, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Stock Rating Reaffirmed by Chardan CapitalChardan Capital reissued a "buy" rating and set a $20.00 target price on shares of Tenaya Therapeutics in a report on Thursday.March 21, 2024 | marketbeat.comLeerink Partnrs Brokers Increase Earnings Estimates for Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Investment analysts at Leerink Partnrs boosted their Q1 2024 earnings per share (EPS) estimates for Tenaya Therapeutics in a report released on Tuesday, March 19th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will poMarch 21, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Tenaya Therapeutics (TNYA)March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Sera Prognostics (SERA)March 21, 2024 | markets.businessinsider.comTenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comTenaya Therapeutics (NASDAQ:TNYA) Given New $18.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group reduced their price objective on shares of Tenaya Therapeutics from $19.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday.March 20, 2024 | marketbeat.comBuy Rating Justified by Tenaya Therapeutics’ Strong Financials and Promising Cardiovascular Pipeline ProgressMarch 19, 2024 | markets.businessinsider.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | finanznachrichten.deTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from AnalystsShares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year prMarch 19, 2024 | marketbeat.comTenaya Therapeutics' (TNYA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Tuesday.March 19, 2024 | marketbeat.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023March 18, 2024 | investorplace.comTenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comTenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications MedicineMarch 18, 2024 | globenewswire.comTimothy Hoey Sells 3,300 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) StockMarch 16, 2024 | insidertrades.comGSA Capital Partners LLP Buys 240,082 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)GSA Capital Partners LLP grew its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 194.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 363,493 shares of the company's stock aftMarch 11, 2024 | marketbeat.comFmr LLC Sells 567,488 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Fmr LLC lowered its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 15.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,186,751 shares of the company's stock after selling 567,488 shares during theMarch 8, 2024 | marketbeat.comTenaya Therapeutics to Participate in Upcoming March Investor ConferencesFebruary 27, 2024 | globenewswire.comTenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature CommunicationsFebruary 26, 2024 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Acquired by Barclays PLCBarclays PLC increased its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 2,635.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 249,558 shares of the company's stock after purchasing an additional 240,436 shares during the period. BarclaFebruary 24, 2024 | marketbeat.com Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Are You Ready for a Small-Cap Rally? (Ad)Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing? Click here to uncover how you can get in on the ground floor. TNYA Media Mentions By Week TNYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNYA News Sentiment▼-0.210.49▲Average Medical News Sentiment TNYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNYA Articles This Week▼01▲TNYA Articles Average Week Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BioAtla News Today Precigen News Today uniQure News Today LianBio News Today Adaptimmune Therapeutics News Today Absci News Today Astria Therapeutics News Today iTeos Therapeutics News Today Y-mAbs Therapeutics News Today Mereo BioPharma Group News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNYA) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.